Evidence map›Paper›PMID 38924644›Full record

ArticleESC heart failure2024

Optimizing heart failure pathways to enhance patient care: the Program to Optimize Heart Failure Patient Pathways (PRO-HF).

Ashish Patwala, Diane Barker, Antoine Da Costa, Geoffrey Bayard, Hans-Peter Brunner-La Rocca, Ricardo Fontes-Carvalho, Luis De la Fuente, Marc Goralski, Niall G Mahon, David Roque and 7 more

Abstract readMulticenter Study
In one paragraph

Article in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ashish PatwalaUniversity Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK.
Diane BarkerUniversity Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK.
Antoine Da CostaCentre Hospitalier Universitaire de Saint-Étienne, Saint-Étienne, France.
Geoffrey BayardCentre Hospitalier Universitaire de Saint-Étienne, Saint-Étienne, France.
Hans-Peter Brunner-La RoccaMaastricht University Medical Centre, Maastricht, The Netherlands.
Ricardo Fontes-CarvalhoCentro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.
Luis De la FuenteHospital Clínico Universitario de Valladolid, Valladolid, Spain.
Marc GoralskiCentre Hospitalier Universitaire d'Orléans, Orléans, France.
Niall G MahonMater Misericordiae Hospital, Dublin, Ireland.
David RoqueHospital Fernando Fonseca, Amadora, Portugal.
Mario SantosCentro Hospitalar Universitário de Santo António, Porto, Portugal.
Zaheer YousefCardiff and Vale University Health Board, Cardiff, UK.
Hela Ben HamoudaMedtronic International Trading Sàrl, Tolochenaz, Switzerland.
Mark TealMedtronic International Trading Sàrl, Tolochenaz, Switzerland.
François ChristoryMedical Education Global Solutions, Paris, France.ORCID 0000-0001-7339-6008
Fozia Zahir AhmedManchester University Hospitals NHS Foundation Trust, Manchester, UK.
Alexandre MebazaaUniversité Paris Cité, Paris, France.ORCID 0000-0001-8715-7753

Funding

Medtronic Europe
6 · The paper itself

Abstract

aimsMany European healthcare providers struggle to adopt multidisciplinary, integrated care pathways for people with heart failure (HF) as recommended by the European Society of Cardiology. PRO-HF (Program to Optimize Heart Failure Patient Pathways) was developed to help clinicians identify strengths, gaps, and shortcomings in their HF pathways and support tailored interventions to optimize pathways and enhance patient care. We report initial findings from baseline assessments of HF pathway characteristics and challenges from 10 hospitals in six European countries (France, Ireland, Portugal, Spain, The Netherlands, and United Kingdom). METHODS AND

resultsBaseline assessments were holistic appraisals of full HF services to calibrate current status and development needs and assist management teams in prioritizing improvement projects. Assessments were performed using a comprehensive checklist of measures covering the HF patient journey from diagnosis to ongoing follow-up. These included a digital survey sent to full HF care teams and one-to-one interviews. The digital survey focused on four key areas (HF outpatient clinic; remote patient management; efficient device implantation and inpatient pathways; and network maximization) and 16 dimensions of excellence. Priority areas and themes for action identified in baseline assessments were (i) provision of HF specialist care; (ii) data capture and analysis; (iii) institutional care protocols; (iv) hospital-wide strategies; and (v) multidisciplinary teams (MDTs). Suboptimal specialist care of emergency inpatients was an issue at all hospitals and prioritized at 8/10. Availability and accessibility of data on patients, activities, and outcomes was an issue at all hospitals and prioritized by 4/10. A lack of clear protocols, templates, and tools for some HF activities created variability in patient care (e.g., HF specialist consultations, diagnostic testing, follow-up appointments, medications, and device eligibility) and inefficient use of clinician time. This made it difficult to initiate new technologies (e.g., remote patient monitoring) due to the risk of overburdening staff. MDTs were frequently understaffed. Multiple interventions were identified to address gaps and shortcomings that could be tailored to specific needs of individual hospitals (e.g., inpatient pathway optimization, creation/optimization of HF outpatient clinics, development of an HF performance dashboard, enhancement of protocol adherence, streamlining cardiac resynchronisation therapy pathways, and MDT coordination).

conclusionsPRO-HF provides a valuable opportunity to identify gaps and significant shortcomings in HF pathways in European hospitals. Preliminary findings from hospitals that have initiated suggested changes to address these challenges are encouraging, though longer-term follow-up from more hospitals is needed to confirm the impact of PRO-HF on HF pathway optimization and patient care.

Indexed as

Critical PathwaysHeart FailureEuropeHumansPatient CarePatient Care TeamQuality ImprovementHeart failureHF pathwayHF protocolHF specialist careMultidisciplinary teamPathway optimizationPRO‐HF

Identifiers

PMID38924644
PMCPMC11424341

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.